The abstract is read at the publisher; the summary is JClub's.
High baseline circulating γδ T cells and early expansion of circulating CD8+PD-1+ T cells predict better outcomes with atezolizumab-bevacizumab in first-line hepatocellular carcinoma.
- Why it matters: Identifying immune biomarkers that forecast response and resistance to AtezoBev in hepatocellular carcinoma remains a key clinical gap.
- What they did: In a prospective cohort of 31 patients, baseline PBMC immunophenotyping, cytokine profiling, and whole-blood RNA-seq were integrated with tumor RNA-seq from GO30140/IMbrave150 (209 AtezoBev; 58 sorafenib) to test immune signatures.
- The result: High baseline circulating γδ T cells linked to disease control (P = 0.006) and longer PFS (P = 0.02), while high intratumoral γδ T cell signature associated with higher response (P < 0.01) and longer PFS/OS only in AtezoBev-treated patients; early CD8+PD-1+ expansion correlated with longer PFS (P = 0.03).
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.